Neuraxis (NRXS) Operating Income (2022 - 2025)
Neuraxis (NRXS) posted Operating Income of -$1.7 million for Q4 2025, up 18.25% sequentially from -$2.1 million in Q3 2025, and down 17.07% YoY from -$2.1 million in Q4 2024.
Neuraxis (NRXS) Operating Income (2022 - 2025) Analysis & Trends
Neuraxis has reported Operating Income for 4 years, with the latest figure at -$1.7 million in Q4 2025.
- Quarterly Operating Income fell 17.07% year-over-year to -$1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.8 million (down 9.4% YoY) and the FY2025 annual result came in at -$7.8 million, down 9.4% from the prior year.
- Operating Income advanced to -$1.7 million in Q4 2025 per NRXS's latest filing, from -$2.1 million in the prior quarter.
- Over five years, Operating Income peaked at -$669582.0 in Q2 2022 and troughed at -$3.0 million in Q3 2023.
- A 4-year average of -$1.6 million and a median of -$1.7 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income tumbled 151.21% in 2023, then soared 45.36% in 2024.
- Over 4 years, Operating Income stood at -$986226.0 in 2022, then slumped by 64.59% to -$1.6 million in 2023, then increased by 9.65% to -$1.5 million in 2024, then retreated by 17.07% to -$1.7 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$1.7 million, -$2.1 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Neuraxis | 75.51 Mn | 67.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.72 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.72 Mn |
| Mar 31, 2025 | -2.30 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Sep 30, 2024 | -1.65 Mn |
| Jun 30, 2024 | -2.21 Mn |
| Mar 31, 2024 | -1.83 Mn |
| Dec 31, 2023 | -1.62 Mn |
| Sep 30, 2023 | -3.02 Mn |
| Jun 30, 2023 | -1.12 Mn |
| Mar 31, 2023 | -896,274.00 |
| Dec 31, 2022 | -986,226.00 |
| Sep 30, 2022 | -1.20 Mn |
| Jun 30, 2022 | -669,582.00 |